SCHEMBL10142823

SCHEMBL10142823

CCCCC(CCCC)NC(=N)N(C=O)CCCCNC(=O)c1ccc(Oc2ccccc2)cc1

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MCHR1 Q99705 2/20 0.46
HDAC3 O15379 2/20 0.45
DRD2 P14416 2/20 0.44
DRD4 P21917 2/20 0.44
DRD3 P35462 2/20 0.44
HDAC1 Q13547 2/20 0.43
HDAC2 Q92769 2/20 0.43
HDAC8 Q9BY41 2/20 0.43
HDAC6 Q9UBN7 2/20 0.43
NAAA Q02083 1/20 0.43
GCGR P47871 1/20 0.43
FOLH1 Q04609 4/20 0.43
NPC1 O15118 2/20 0.41
RAB9A P51151 2/20 0.41
MEN1 O00255 2/20 0.41
KMT2A Q03164 2/20 0.41
CA12 O43570 1/20 0.41
CA1 P00915 1/20 0.41
CA2 P00918 1/20 0.41
MMP2 P08253 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12504004 0.97 MCHR1 (0.47) MCHR1HDAC3DRD2DRD4DRD3
SCHEMBL8412186 0.83 RECQL (0.51) NPC1RAB9A
SCHEMBL7603836 0.80 NAAA (0.44) NAAA
SCHEMBL12499263 0.79 NAAA (0.43) NAAA
SCHEMBL8411133 0.79 HPGD (0.57) HDAC3HDAC1HDAC2HDAC8HDAC6
SCHEMBL12499872 0.78 ACKR3 (0.46) HDAC1HDAC2HDAC8HDAC6KMT2A
SCHEMBL12499962 0.77 PAOX (0.41) DRD3FOLH1
SCHEMBL27571120 0.76 NAAA (0.72) MCHR1HDAC3DRD2DRD4DRD3
SCHEMBL7600641 0.73 PAOX (0.39) FOLH1
SCHEMBL13886658 0.73 MCHR1 (0.62) MCHR1DRD2DRD4DRD3NPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8178513-B2 Heterocyclic aspartyl protease inhibitors SCHERING CORPORATION (US) 2012-05-15 US disclosed
US-7973067-B2 Heterocyclic aspartyl protease inhibitors SCHERING CORPORATION (US) 2011-07-05 US disclosed
US-20090306047-A1 HETEROCYCLIC ASPARTYL PROTEASE INHIBITORS SCHERING CORPORATION 2009-12-10 US disclosed
US-20090258868-A1 HETEROCYCLIC ASPARTYL PROTEASE INHIBITORS SCHERING CORPORATION 2009-10-15 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090306047-A1 HETEROCYCLIC ASPARTYL PROTEASE INHIBITORS PRSS1, BCHE, CTSZ MCHR1 1522/4885HDAC3 1024/4885DRD2 593/4885
US-20090258868-A1 HETEROCYCLIC ASPARTYL PROTEASE INHIBITORS CHRM1, CHRM2, PRSS1 MCHR1 830/4885HDAC3 978/4885DRD2 440/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.